Entero Therapeutics Plunges 13.84% Amid Short Interest Surge

Entero Therapeutics' stock experienced a significant drop of 13.84% in pre-market trading on August 12, 2025, reflecting a notable shift in investor sentiment.

Entero Therapeutics has a substantial short interest, with 648,700 shares representing 14.61% of the float. This high level of short interest indicates that a significant portion of the available shares are being sold short, which can contribute to increased volatility and potential downward pressure on the stock price.

Entero Therapeutics recently raised $3 million through the sale of warrants, which initially boosted premarket shares by 53%. This financial maneuver included an initial $1 million at closing, with an additional $2 million contingent upon the activation of a resale registration statement. The strategic sale of pre-funded and common stock warrants has captured the attention of institutional investors, reflecting optimistic sentiment and a positive outlook from analysts.

Wall Street analysts have set a one-year price target of $36.00 for Entero Therapeutics, suggesting a remarkable potential upside of 9,765.72% from the current share price. This optimistic forecast, along with an "Outperform" consensus among brokerage firms, indicates strong confidence in the company's future performance. The average brokerage recommendation score of 2.5 signals a positive outlook, with a scale from 1 to 5, where 1 is a "Strong Buy" and 5 is a "Sell."